ACH ACCENDRA HEALTH INC/VA/
Wholesale-Medical, Dental & Hospital Equipment & Supplies · NYSE · SEC CIK 75252 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.0%
TTM net income YoY-195.8%
TTM EPS YoY-195.6%
Revenue 3-yr CAGR-35.4%
Net income 3-yr CAGR—
Margins
Gross margin46.0%
Operating margin0.9%
Net margin-39.8%
FCF margin-10.7%
EBITDA margin8.2%
Returns
ROE-2,037.6%
ROA-29.8%
ROIC (approx.)1.0%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets119.2%
Debt / equity—
Current ratio0.49x
Interest coverage0.22x
Cash quality & payout
Operating cash flow / net income0.11x
Accruals ratio-26.5%
Payout ratio—
Capex / revenue6.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.76B | $2.68B | $2.55B | $9.96B | $9.79B |
| Cost of revenue | $1.47B | $1.40B | $1.34B | $8.13B | $8.27B |
| Gross profit | $1.29B | $2.22B | $2.13B | $1.83B | $1.51B |
| R&D expense | — | $13.00M | $13.00M | $12.00M | $12.10M |
| SG&A expense | $1.07B | $1.08B | $1.00B | $1.55B | $1.08B |
| Operating income | $27.46M | -$217.73M | $133.23M | $142.91M | $368.47M |
| Interest expense | $107.18M | $107.57M | $116.77M | $128.89M | $48.09M |
| Pretax income | -$101.95M | -$329.88M | $15.27M | $10.89M | $276.75M |
| Income tax | $729,000 | $20.85M | $6.36M | -$11.50M | $55.16M |
| Net income | -$1.10B | -$362.69M | -$41.30M | $22.39M | $221.59M |
| EBITDA | $241.98M | -$36.45M | $343.60M | $371.58M | $459.09M |
| EPS (basic) | -14.31 | -4.73 | -0.54 | 0.30 | 3.05 |
| EPS (diluted) | -14.31 | -4.73 | -0.53 | 0.29 | 2.94 |
| Dividends declared per share | — | — | — | — | 0.01 |
| Weighted avg. shares (diluted) | 76.90M | 76.74M | 77.37M | 76.22M | 75.49M |
| Balance sheet | |||||
| Cash & equivalents | $281.99M | $27.57M | $272.92M | $86.19M | $72.03M |
| Inventory | $74.44M | $67.58M | $1.11B | $1.33B | $1.50B |
| Current assets | $547.87M | $2.02B | $2.10B | $2.30B | $2.32B |
| PP&E, net | $256.16M | $249.28M | $543.97M | $578.27M | $317.24M |
| Goodwill | $1.23B | $1.23B | $1.64B | $1.64B | $390.19M |
| Intangibles | $136.47M | $210.06M | $361.83M | $445.04M | $209.75M |
| Total assets | $2.45B | $4.66B | $5.09B | $5.39B | $3.54B |
| Current liabilities | $947.08M | $1.85B | $1.89B | $1.57B | $1.34B |
| Short-term debt | $250.00M | $42.87M | $206.90M | $17.91M | — |
| Long-term debt | $1.80B | $1.80B | $1.89B | $2.48B | $947.54M |
| Total debt | $2.05B | $1.84B | $2.10B | $2.50B | $947.54M |
| Total liabilities | $2.91B | $4.07B | $4.17B | $4.44B | $2.60B |
| Shareholders' equity | -$460.98M | $586.36M | $945.30M | $966.74M | $938.50M |
| Net debt | $1.77B | $1.81B | $1.82B | $2.41B | $875.50M |
| Shares outstanding | 76.39M | 77.20M | 76.55M | 76.28M | 75.43M |
| Cash flow statement | |||||
| Operating cash flow | -$101.79M | $161.50M | $740.71M | $325.01M | $124.18M |
| Capital expenditure | $190.96M | $170.29M | $172.38M | $158.09M | $40.98M |
| Free cash flow | -$292.75M | -$8.79M | $568.34M | $166.92M | $83.19M |
| Investing cash flow | $144.42M | -$116.53M | -$137.25M | -$1.80B | -$53.63M |
| Financing cash flow | $188.08M | -$267.60M | -$417.33M | $1.50B | -$129.48M |
| Depreciation & amortization | $214.52M | $181.28M | $210.37M | $228.67M | $90.62M |
| Stock-based compensation | $12.87M | $16.64M | $14.39M | $20.99M | $25.02M |
| Dividends paid | — | — | $0 | $0 | $731,000 |
| Share buybacks | $10.18M | — | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.